Epinastine


Concise Prescribing Info
Indications/Uses
Allergic conjunctivitis.
Dosage/Direction for Use
Adult : Ophth As 0.05% soln: Instill 1 drop into each eye bid.
Dosage Details
Ophthalmic
Allergic conjunctivitis
Adult: As 0.05% soln: Instill 1 drop into each eye bid.
Child: ≥12 yr Same as adult dose.
Special Precautions
Pregnancy and lactation.
Adverse Reactions
Nervous: Headache.
GI: Taste disturbance.
Resp: Upper resp infection, cough, rhinitis, sinusitis, pharyngitis.
Ophthalmologic: Burning sensation, folliculosis, conjunctival hyperaemia, dryness, pain, pruritus, increased lacrimation, visual disturbance.
Patient Counseling Information
Remove contact lenses prior to instillation and may be reinserted after 10-15 min.
Action
Description: Epinastine, a selective H1-receptor antagonist, inhibits the release of histamine from mast cells. It also possesses affinity to H2, α1, α 2, and 5-HT2  receptors.
Onset: 3-5 min.
Duration: 8 hr.
Pharmacokinetics:
Absorption: Minimal systemic absorption after topical application. Time to peak plasma concentration: Approx 2 hr.
Distribution: Volume of distribution: 417 L. Plasma protein binding: 64%.
Metabolism: >10% is metabolised.
Excretion: Via urine (as unchanged drug). Terminal elimination half-life: 12 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store between 20-25°C.
ATC Classification
S01GX10 - epinastine ; Belongs to the class of other ophthalmologic antiallergics.
Disclaimer: This information is independently developed by MIMS based on Epinastine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Relestat
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in